We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best ...

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most si ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...

In critically ill children requiring mechanical ventilation, inhaled isoflurane shows sedation efficacy comparable to the routinely used intravenous sedative midazolam.

By Dennis Thompson HealthDay ReporterTHURSDAY, July 24, 2025 (HealthDay News) — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says.

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer's disease treatments: Intranasal insulin, delivered via a simple ...